Active — Not RecruitingPhase 2

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

China104 participantsStarted 2024-02-05

Plain-language summary

To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. History of invasive breast cancer.
✕. Occurrence of any other malignant tumors within the last 3 years or current simultaneous presence.
✕. Underwent significant surgical treatment, incisional biopsy, or significant trauma within 28 days before the start of the study.
✕. Unhealed wounds or fractures.
✕. Ocular diseases deemed clinically significant by the investigator.
✕. Occurrence of arterial/deep venous thrombotic events within the last 6 months.
✕. History of substance abuse with inability to quit or individuals with mental disorders.
✕. ≥ Grade 2 myocardial ischemia or infarction, arrhythmias, or ≥ Grade 2 congestive heart failure.

Total physiological complete response (tpCR)

Timeframe: Up to 12 months.

NCT IDNCT06198751

SponsorChia Tai Tianqing Pharmaceutical Group Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-05-08